SK 763. Antitumor Activity of Actinonin

Summary of Invention

Actinonin, an antibiotic and CD13/aminopeptidase N inhibitor, has been shown to be cytotoxic to human tumor cell lines in vitro and to have anti-tumor effects on mouse leukemia in vivo.

In vitro, actinonin inhibits growth of human leukemia and lymphoma cells (NB4, HL60, RAJI, and DAUDI) with an IC50 of about 2-5 g/mL.

In vivo, using the syngeneic AKR mouse leukemia model, actinonin showed dose dependent anti-tumor effects with a significant survival advantage at a dose of 100 g. Moreover, anti-cancer activity was seen in vivo without significant toxicity. The antiproliferative effects of actinonin on the tumor cells are not mediated by inhibition of CD13/aminopeptidase N.

Advantages

Method of treating cancers using actinonin.

Areas of Application

Therapeutic drug.

Stage of Development

In vivo studies in progress.

Lead Inventor

Dr. David A. Scheinberg

Patent Information

US patent prosecution ongoing.

References

Xu Y, et al. Clin Cancer Res. 4:171-6 (1998).

Related Invention

SK1295: Human peptide deformylase crystal structure and uses thereof

Contact Information

Viviane Martin, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: martinv@mskcc.org